1615 related articles for article (PubMed ID: 27488518)
61. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
[TBL] [Abstract][Full Text] [Related]
62. Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.
Segal E; Martens M; Wang HL; Brazauskas R; Weisdorf D; Sandmaier BM; Khoury HJ; de Lima M; Saber W
Cancer; 2017 Sep; 123(17):3346-3355. PubMed ID: 28452054
[TBL] [Abstract][Full Text] [Related]
63. Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.
Gupta V; Tallman MS; He W; Logan BR; Copelan E; Gale RP; Khoury HJ; Klumpp T; Koreth J; Lazarus HM; Marks DI; Martino R; Rizzieri DA; Rowe JM; Sabloff M; Waller EK; DiPersio JF; Bunjes DW; Weisdorf DJ
Blood; 2010 Sep; 116(11):1839-48. PubMed ID: 20538804
[TBL] [Abstract][Full Text] [Related]
64. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
65. [A comparative study of unrelated donor and matched-sibling donor allogeneic hematopoietic stem cell transplantation in children and adolescents with acquired severe aplastic anemia].
Zhou J; Fu YW; Liang LJ; Wang Q; Han LJ; Zu YL; Zhang Y; Zhu XH; Yu FK; Fang BJ; Wei XD; Song YP
Zhonghua Nei Ke Za Zhi; 2016 Dec; 55(12):927-931. PubMed ID: 27916046
[No Abstract] [Full Text] [Related]
66. Impact of Thymoglobulin by Stem Cell Source (Peripheral Blood Stem Cell or Bone Marrow) After Myeloablative Stem Cell Transplantation From HLA 10/10-Matched Unrelated Donors: A Report From the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
Ravinet A; Cabrespine A; Socié G; Milpied N; Yakoub Agha I; Nguyen S; Michallet M; Menard AL; Maillard N; Mohty M; Suarez F; Huynh A; Marchand T; Deteix C; Cassuto JP; Maury S; Chevallier P; Reman O; Peffault de Latour R; Bay JO
Transplantation; 2016 Aug; 100(8):1732-9. PubMed ID: 26528768
[TBL] [Abstract][Full Text] [Related]
67. [Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission].
Bondarenko SN; Semenova EV; Vavilov VN; Stancheva NV; Morozova EV; Alianskiĭ AL; Babenko EV; Osipova NÉ; Zubarovskaia LS; Afanas'ev BV
Ter Arkh; 2013; 85(7):18-25. PubMed ID: 24137943
[TBL] [Abstract][Full Text] [Related]
68. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).
Aoudjhane M; Labopin M; Gorin NC; Shimoni A; Ruutu T; Kolb HJ; Frassoni F; Boiron JM; Yin JL; Finke J; Shouten H; Blaise D; Falda M; Fauser AA; Esteve J; Polge E; Slavin S; Niederwieser D; Nagler A; Rocha V;
Leukemia; 2005 Dec; 19(12):2304-12. PubMed ID: 16193083
[TBL] [Abstract][Full Text] [Related]
69. Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
Malard F; Labopin M; Cho C; Blaise D; Papadopoulos EB; Passweg J; O'Reilly R; Forcade E; Maloy M; Volin L; Castro-Malaspina H; Hicheri Y; Jakubowski AA; Orvain C; Giralt S; Mohty M; Nagler A; Perales MA
J Hematol Oncol; 2018 Oct; 11(1):127. PubMed ID: 30342553
[TBL] [Abstract][Full Text] [Related]
70. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
71. Outcomes of haploidentical peripheral stem cell transplantation with combination of post-transplant cyclophosphamide (PTCy) and anti-thymocyte globulin (ATG) compared to unrelated donor transplantation in acute myeloid leukemia: A retrospective 10-year experience.
Barkhordar M; Kasaeian A; Janbabai G; Mousavi SA; Fumani HK; Tavakoli S; Bahri T; Ghavamzadeh A; Vaezi M
Leuk Res; 2022 Sep; 120():106918. PubMed ID: 35843087
[TBL] [Abstract][Full Text] [Related]
72. Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.
Chevallier P; Labopin M; Socie G; Rubio MT; Blaise D; Vigouroux S; Huynh A; Michallet M; Bay JO; Maury S; Yakoub-Agha I; Fegueux N; Deconinck E; Contentin N; Maillard N; Bulabois CE; Francois S; Oumedaly R; Raus N; Mohty M
Eur J Haematol; 2015 May; 94(5):449-55. PubMed ID: 25238651
[TBL] [Abstract][Full Text] [Related]
73. Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502.
Devine SM; Owzar K; Blum W; Mulkey F; Stone RM; Hsu JW; Champlin RE; Chen YB; Vij R; Slack J; Soiffer RJ; Larson RA; Shea TC; Hars V; Sibley AB; Giralt S; Carter S; Horowitz MM; Linker C; Alyea EP
J Clin Oncol; 2015 Dec; 33(35):4167-75. PubMed ID: 26527780
[TBL] [Abstract][Full Text] [Related]
74. Long-term outcome of unrelated donor transplantation for AML using myeloablative conditioning incorporating pretransplant Alemtuzumab.
Das-Gupta EP; Russell NH; Shaw BE; Pearce RM; Byrne JL
Biol Blood Marrow Transplant; 2007 Jun; 13(6):724-33. PubMed ID: 17531783
[TBL] [Abstract][Full Text] [Related]
75. Missing HLA C group 1 ligand in patients with AML and MDS is associated with reduced risk of relapse and better survival after allogeneic stem cell transplantation with fludarabine and treosulfan reduced toxicity conditioning.
Shimoni A; Vago L; Bernardi M; Yerushalmi R; Peccatori J; Greco R; Shem-Tov N; Lo Russo A; Danylesko I; Apel A; Bonini C; Lupo Stanghellini MT; Nagler A; Ciceri F
Am J Hematol; 2017 Oct; 92(10):1011-1019. PubMed ID: 28631269
[TBL] [Abstract][Full Text] [Related]
76. [Efficacy analysis of unrelated donor hematopoietic stem cell transplantation for treatment of high risk acute myeloid leukemia].
Ye F; Tang XW; Sun AN; Qiu HY; Jin ZM; Fu ZZ; Chen F; Wu DP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):696-701. PubMed ID: 23815925
[TBL] [Abstract][Full Text] [Related]
77. Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.
Lorentino F; Labopin M; Bernardi M; Ciceri F; Socié G; Cornelissen JJ; Esteve J; Ruggeri A; Volin L; Yacoub-Agha I; Craddock C; Passweg J; Blaise D; Gedde-Dahl T; Poiani M; Fegueux N; Mohty M; Nagler A;
Am J Hematol; 2018 Oct; 93(10):1236-1244. PubMed ID: 30058714
[TBL] [Abstract][Full Text] [Related]
78. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: A retrospective analysis of 537 patients from the Acute Leukemia Working Party of the EBMT.
Christopeit M; Labopin M; Gorin NC; Saraceni F; Passweg J; Forcade E; Maertens J; Van Lint MT; Bosi A; Niederwieser D; Ehninger G; Polge E; Mohty M; Nagler A
Am J Hematol; 2018 Dec; 93(12):1532-1542. PubMed ID: 30218444
[TBL] [Abstract][Full Text] [Related]
79. Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Salvatore D; Labopin M; Ruggeri A; Battipaglia G; Ghavamzadeh A; Ciceri F; Blaise D; Arcese W; Sociè G; Bourhis JH; Van Lint MT; Bruno B; Huynh A; Santarone S; Deconinck E; Mohty M; Nagler A
Haematologica; 2018 Aug; 103(8):1317-1328. PubMed ID: 29748438
[TBL] [Abstract][Full Text] [Related]
80. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
